Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity Pharmaceutical Investing
Aurinia Presents Data Demonstrating LUPKYNIS® is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations Pharmaceutical Investing
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company Pharmaceutical Investing
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia Improved Survival in People Hospitalized with COVID-19 Pharmaceutical Investing
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing Pharmaceutical Investing
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs Pharmaceutical Investing
